What is the 13F Pro Quality Score for KNSA?

13F Pro ranks Kiniksa Pharmaceuticals International, plc (KNSA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View KNSA's current score at https://13fpro.ai/research/KNSA (free sign-up required for the full ranking).

Which hedge funds own the most KNSA stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of KNSA include FMR, Rubric Capital Management, BAKER BROS. ADVISORS. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/KNSA as soon as new 13F filings post.

Where does 13F Pro source KNSA data?

All Kiniksa Pharmaceuticals International, plc fundamentals and ownership data come directly from SEC EDGAR. Kiniksa Pharmaceuticals International, plc files with the SEC under CIK 1730430. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is KNSA in?

Kiniksa Pharmaceuticals International, plc (KNSA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is KNSA research updated on 13F Pro?

KNSA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Kiniksa Pharmaceuticals International, plc(KNSA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1730430 KNSA stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

KNSA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Kiniksa Pharmaceuticals International, plc (KNSA), a Healthcare sector company. KNSA is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Kiniksa Pharmaceuticals International, plc reports quarterly revenue of $214.3M, net income of $22.6M, an operating margin of 13.7%. Top institutional holders of KNSA by reported 13-F value include FMR, Rubric Capital Management, BAKER BROS. ADVISORS, based on the most recent SEC filings. KNSA trades on the Nasdaq exchange and files with the SEC under CIK 1730430. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KNSA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Kiniksa Pharmaceuticals International, plc directly from SEC EDGAR.

Revenue

Q1 2026

$214.3M

Net Income

Q1 2026

$22.6M

Free Cash Flow

Q1 2026

$50.0M

Operating Margin

Q1 2026

13.7%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+60.1% YoY

$677.6MFY 2025

FY21 $38.5MFY23 $270.3MFY24 $423.2MFY25 $677.6M

Net Income

+236.6% YoY

$59.0MFY 2025

FY21 $-157.9MFY23 $14.1MFY24 $-43.2MFY25 $59.0M

Operating Income

+269.3% YoY

$77.2MFY 2025

FY21 $-156.6MFY23 $-25.2MFY24 $-45.6MFY25 $77.2M

EPS (Diluted)

+225.0% YoY

$0.75FY 2025

FY21 $-2.30FY23 $0.20FY24 $-0.60FY25 $0.75

Total Assets

+31.5% YoY

$763.6MFY 2025

FY21 $232.8MFY23 $526.3MFY24 $580.6MFY25 $763.6M

Op. Cash Flow

+437.1% YoY

$138.0MFY 2025

FY21 $-126.3MFY23 $13.3MFY24 $25.7MFY25 $138.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2021	FY 2020	FY 2019
Revenue	$677.6M +60.1%	$423.2M +56.6%	$270.3M +601.2%	$38.5M	—	—
Net Income	$59.0M +236.6%	$-43.2M -406.7%	$14.1M +108.9%	$-157.9M +2.1%	$-161.4M +0.3%	$-161.9M
Operating Income	$77.2M +269.3%	$-45.6M -81.0%	$-25.2M +83.9%	$-156.6M +0.5%	$-157.4M +7.4%	$-170.0M
EPS (Diluted)	$0.75 +225.0%	$-0.60 -400.0%	$0.20 +108.7%	$-2.30 +11.9%	$-2.61 +12.7%	$-2.99
Total Assets	$763.6M +31.5%	$580.6M +10.3%	$526.3M +126.1%	$232.8M -33.4%	$349.5M +37.3%	$254.5M
Operating Cash Flow	$138.0M +437.1%	$25.7M +93.1%	$13.3M +110.5%	$-126.3M +7.5%	$-136.5M +13.8%	$-158.4M

AI Insight: KNSA Financial Trends

KNSA achieved profitability turnaround with revenue nearly doubling from $109M in Q2 2024 to $214M in Q1 2026.

• Revenue accelerated from $109M in Q2 2024 to $214M in Q1 2026, representing 96% growth over eight quarters.

• Company turned profitable with net income swinging from -$4M in Q2 2024 to $23M in Q1 2026.

• Operating cash flow strengthened from $5M in Q2 2024 to $50M in Q1 2026.

• Equity base expanded from $435M to $606M over the eight-quarter period with no debt.

⚠ Net income declined from $18M in both Q2 and Q3 2025 to $14M in Q4 2025.

⚠ Operating income dropped from $24M in Q3 2025 to $20M in Q4 2025 despite revenue growth.

AI Insight: KNSA Ratio Trends

Kiniksa achieved dramatic profitability turnaround, with operating margin swinging from -15.8% in Q4 2024 to 13.7% in Q1 2026.

• Operating margin turned positive in Q1 2025 at 9.6% after three consecutive negative quarters, reaching 13.7% in Q1 2026.

• ROIC surged from -17.6% in Q4 2024 to 19.3% in Q1 2026, demonstrating strong capital efficiency improvement.

• Net profit margin consistently positive since Q1 2025, expanding from 6.2% to 10.5% in the latest quarter.

• ROE strengthened to 14.9% in Q1 2026, up from 7.5% in Q1 2025 when profitability first returned.

⚠ Operating margin declined to 9.8% in Q4 2025 from 13.3% in Q3 2025, breaking sequential improvement trend.

⚠ Quarterly margin volatility persists despite overall profitability improvement, suggesting potential business seasonality or execution challenges.

Get alerted when KNSA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Kiniksa Pharmaceuticals International, plc including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of KNSA

FMR LLC
$328.6M6,823,700 sh
Rubric Capital Management LP
$180.6M3,750,000 sh
BAKER BROS. ADVISORS LP
$136.1M2,826,246 sh
TANG CAPITAL MANAGEMENT LLC
$108.8M2,259,889 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$85.0M1,766,268 sh
VANGUARD CAPITAL MANAGEMENT LLC
$64.2M1,333,093 sh
Caption Management, LLC
$48.1M999,400 sh
MORGAN STANLEY
$48.0M997,786 sh
D. E. Shaw & Co., Inc.
$46.2M959,257 sh
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP
$43.0M892,666 sh

Fund	Value	Shares
FMR LLC	$328.6M	6,823,700
Rubric Capital Management LP	$180.6M	3,750,000
BAKER BROS. ADVISORS LP	$136.1M	2,826,246
TANG CAPITAL MANAGEMENT LLC	$108.8M	2,259,889
VANGUARD PORTFOLIO MANAGEMENT LLC	$85.0M	1,766,268
VANGUARD CAPITAL MANAGEMENT LLC	$64.2M	1,333,093
Caption Management, LLC	$48.1M	999,400
MORGAN STANLEY	$48.0M	997,786
D. E. Shaw & Co., Inc.	$46.2M	959,257
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	$43.0M	892,666

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put KNSA on your watchlist

Track score changes the day Kiniksa Pharmaceuticals International, plc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is KNSA a good stock to buy?

13F Pro's AI-powered analysis of Kiniksa Pharmaceuticals International, plc (KNSA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for KNSA are available on the KNSA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own KNSA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling KNSA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Kiniksa Pharmaceuticals International, plc's investment landscape.